Patient-derived xenograft models: an emerging platform for translational cancer research. by Hidalgo, Manuel et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
Physiology and Medical Physics Articles Department of Physiology and Medical Physics
1-1-2014
Patient-derived xenograft models: an emerging
platform for translational cancer research.
Manuel Hidalgo
Centro Nacional de Investigaciones Oncológicas, Madrid
Frederic Amant
Katholieke Universiteit Leuven
Andrew V. Biankin
University of Glasgow
Eva Budinská
Masaryk University
Annette T. Byrne
Royal College of Surgeons in Ireland
See next page for additional authors
This Article is brought to you for free and open access by the Department
of Physiology and Medical Physics at e-publications@RCSI. It has been
accepted for inclusion in Physiology and Medical Physics Articles by an
authorized administrator of e-publications@RCSI. For more information,
please contact epubs@rcsi.ie.
Citation
Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman
S, Seoane J, Trusolino L, Villanueva A. Patient-derived xenograft models: an emerging platform for translational cancer research.
Cancer Discovery. 2014(9):998-1013.
Authors
Manuel Hidalgo, Frederic Amant, Andrew V. Biankin, Eva Budinská, Annette T. Byrne, Carlos Caldas, Robert
B. Clarke, Steven de Jong, Jos Jonkers, Gunhild Mari Mælandsmo, Sergio Roman-Roman, Joan Seoane, Livio
Trusolino, and Alberto Villanueva
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/physiolart/90
— Use Licence —
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/physiolart/90
	 1	
Patient	Derived	Xenograft	Models:		An	Emerging	Platform	for	Translational	Cancer	
Research	
	
Authors:	 	 Manuel	 Hidalgo1,	 Frederic	 Amant2,	 Andrew	 V.	 Biankin3,	 Eva	 Budinská4,	
Annette	 T.	 Byrne5,	 Carlos	 Caldas6,	 Robert	 B.	 Clarke7,	 Steven	 de	 Jong8,	 Jos	 Jonkers9,	
Gunhild	Mari	Mælandsmo10,	Sergio	Roman-Roman11,	Joan	Seoane12,	Livio	Trusolino13,14	
and	Alberto	Villanueva15	for	the	EurOPDX	Consortium*	
	
Institutions:	 	 1Centro	 Nacional	 de	 Investigaciones	 Oncológicas,	 Madrid,	 Spain;	
2Katholieke	 Universiteit	 Leuven,	 Belgium;	 3Wolfson	 Wohl	 Cancer	 Research	 Centre,	
Institute	of	Cancer	Sciences,	University	of	Glasgow,	Glasgow,	UK;	4Masaryk	University,	
Brno,	 Czech	 Republic;	 5Royal	 College	 of	 Surgeons	 in	 Ireland,	 Dublin,	 Ireland;	
6Cambridge	Cancer	Centre,	Cambridge,	UK;	7Institute	of	Cancer	Sciences,	University	of	
Manchester,	UK;	 8University	Medical	Centre	Groningen,	Groningen,	The	Netherlands;	
9The	 Netherlands	 Cancer	 Institute,	 Amsterdam,	 The	 Netherlands;	 10Oslo	 University	
Hospital,	 Oslo,	 Norway;	 11Institut	 Curie,	 Paris,	 France;	 12Vall	 d'Hebron	 Institute	 of	
Oncology,	Barcelona,	Spain;	13Candiolo	Cancer	Institute	–	FPO	IRCCS	and	14Department	
of	 Oncology,	 University	 of	 Torino,	 Candiolo,	 Torino,	 Italy;	 15Catalan	 Institute	 of	
Oncology-Bellvitge	Biomedical	Research	Institute,	L’Hospitalet	de	Llobregat,	Barcelona,	
Spain	
	
Running	Title:		PDX	Cancer	Models	
	
	
	 2	
	
Key	 Words:	 	 PDX,	 Mouse	 Models,	 Preclinical	 Studies,	 Avatar,	 Xenopatient,	
Orthoxenografts,	Tumorgraft	
	
Abbreviations	list:	CNAs:	copy	number	alterations;	CRC:	colorectal	cancer;	CSC:	cancer	
stem	 cell;	 GEM:	 genetically	 engineered	 mouse;	 HBC:	 human	 breast	 cancer;	 NSCLC:	
non-small	 cell	 lung	 cancer;	 PDAC:	 pancreatic	 ductal	 adenocarcinoma;	 PDX:	 patient	
derived	tumor	xenograft;	RCC:	renal	cell	carcinoma;	SCCHN:	squamous	cell	carcinoma	
of	the	head	and	neck;		
	
Word	count:	7449	
Figures:	3;	Supplementary	Figures:	1	
Tables:	3;	Supplementary	Tables:	2	
	
Notes:	 With	 the	 exception	 of	 Manuel	 Hidalgo,	 all	 authors	 are	 listed	 alphabetically.	
Correspondence	 should	 be	 addressed	 to	Manuel	 Hidalgo,	 CNIO,	Melchor	 Fernandez	
Almagro	3,	28029,	Madrid,	Spain,	Phone:		+	34	91	732	8000,	mhidalgo@cnio.es.		MH	is	
a	founder	and	shareholder	of	Champions	Oncology,	Inc.	
	 3	
ABSTRACT	
	
Recently,	there	has	been	increasing	interest	 in	the	development	and	characterization	
of	 patient	 derived	 tumor	 xenograft	 (PDX)	 models	 for	 cancer	 research.	 PDX	 models	
mostly	retain	the	principal	histological	and	genetic	characteristics	of	their	donor	tumor	
and	remain	stable	across	passages.	These	models	have	been	shown	to	be	predictive	of	
clinical	 outcomes	 and	 are	 being	 used	 for	 preclinical	 drug	 evaluation,	 biomarker	
identification,	 biological	 studies,	 and	 personalized	 medicine	 strategies.	 This	 paper	
summarizes	 the	 current	 state	of	 the	art	 in	 this	 field	 including	methodological	 issues,	
available	 collections,	 practical	 applications,	 challenges	 and	 shortcoming,	 and	 future	
directions,	and	introduces	a	European	consortium	of	PDX	models.	
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STATEMENT	OF	SIGNIFICANCE	
	
PDX	models	are	 increasingly	used	 in	 translational	 cancer	 research.	These	models	are	
useful	 for	 drug	 screening,	 biomarker	 development	 and	 the	 preclinical	 evaluation	 of	
personalized	medicine	 strategies.	 This	 review	 provides	 a	 timely	 overview	 of	 the	 key	
characteristics	 of	 PDX	 models	 and	 a	 detailed	 discussion	 on	 future	 directions	 in	 the	
field.		
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INTRODUCTION	
	
	 The	 use	 of	 preclinical	 models	 is	 a	 core	 component	 in	 every	 aspect	 of	
translational	cancer	research	ranging	from	the	biological	understanding	of	the	disease	
to	the	development	of	new	treatments	(1,	2).	With	regard	to	drug	development,	the	
use	of	human	cancer	models	for	drug	screening	began	at	the	National	Cancer	Institute	
(USA)	 in	 the	 70s	 following	 a	 nearly	 three-decade	 period	 in	 which	 screening	 of	 new	
drugs	 was	 performed	 in	 rapidly	 growing	 murine	 models.	 Over	 the	 last	 40	 years,	 a	
number	of	studies	have	established	basic	methodology	and	a	systematic	approach	for	
preclinical	 testing	of	anticancer	agents	both	 in	 vitro	 and	 in	 vivo	 (1,	2).	Currently,	 the	
NCI-60	 cancer	 cell	 line	 panel	 represents	 the	 best	 characterized	 and	most	 frequently	
used	 collection	 of	 human	 cancer	 models	 utilized	 for	 in	 vitro	 drug	 screening	 and	
development	 (3).	 These	 cells	 were	 derived	 from	 cancer	 patients	 and	 have	 been	
adapted	 to	grow	 indefinitely	 in	 artificial	 culture	 conditions.	Xenografts	developed	by	
growing	 these	 cell	 lines	 subcutaneously	 in	 immunodeficient	 mice	 are	 the	 most	
commonly	used	in	vivo	platform	in	preclinical	drug	development.			
	
These	so-called	conventional	cell	lines,	while	convenient	and	easy	to	use,	have	
important	 limitations	 in	preclinical	drug	development.	The	most	relevant	 is	their	 lack	
of	 predictive	 value	 with	 regards	 to	 activity	 in	 specific	 cancer	 types	 in	 clinical	 trials.	
While	in	general,	agents	active	in	at	least	one	third	of	the	preclinical	models	explored	
to	 date	 showed	activity	 in	 phase	 II	 clinical	 trials,	 there	has	 been	poor	 prediction	 for	
activity	 in	 specific	 disease	 entities,	 except	 in	 lung	 cancer	 (4).	 While	 the	 underlying	
cause	of	 this	 limited	predictive	 value	 is	not	 fully	understood,	 evidence	 suggests	 that	
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the	process	of	generating	cancer	cell	lines	results	in	major	and	irreversible	alterations	
in	 biological	 properties,	 including	 gain	 and	 loss	 of	 genetic	 information,	 alteration	 in	
growth	and	invasion	properties,	and	loss	of	specific	cell	populations	(5,	6).	In	addition,	
cell	lines	are	usually	established	only	from	the	more	aggressive	tumors	and	hence	are	
not	representative	of	complex	tumor	heterogeneity	evident	in	the	clinic.	For	all	these	
reasons,	the	establishment	of	cell	lines	is	not	an	appropriate	strategy	for	personalized	
medicine	 applications.	 Novel	 approaches,	 such	 as	 short-term	 primary	 cultures	 or	
organoids,	 are	 being	 developed,	 although	 important	 validation	 studies	 are	 still	
required	prior	to	any	application	in	conventional	preclinical	screening	projects.	
	
In	an	attempt	to	circumvent	these	issues,	there	has	been	an	increasing	interest	
in	 the	 application	 of	 more	 advanced	 preclinical	 cancer	 models	 including	 patient	
derived	 tumor	 xenografts	 (PDX)	 as	 well	 as	 genetically	 engineered	 mouse	 (GEM)	
models.		PDX	models	are	not	new,	and	studies	conducted	in	the	80s	already	showed	a	
high	 degree	 of	 correlation	 between	 clinical	 response	 to	 cytotoxic	 agents	 in	 adult	
patients	with	 lung	cancer	and	 response	 to	 the	same	agent	 in	PDX	models	generated	
from	 these	 patients	 (7).	 Similar	 observations	 were	 made	 in	 studies	 of	 childhood	
rhabdomyosarcomas	 (8).	 In	 addition,	 PDX	 models	 have	 been	 used	 to	 conduct	
preclinical	 phase	 II	 studies	with	 classic	 chemotherapeutics	 (9).	 In	 recent	 years	 there	
has	been	 renewed	 interest	 in	 the	development	of	PDX	models	 from	different	 tumor	
types.	 Indeed,	 these	 models	 are	 becoming	 the	 preferred	 preclinical	 tool	 in	 both	
industry	and	academic	groups	in	an	attempt	to	improve	the	drug	development	process	
(10-12).	 	 Currently,	 there	 are	 several	 collections	 of	 extensively	 characterized	 PDX	
models	 in	 use	 for	 different	 translational	 research	 applications.	 These	 collections	
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broadly	represent	the	complex	clinical	tumor	heterogeneity	and	molecular	diversity	of	
human	 cancers.	 In	 this	 paper	we	 review	 current	methodology	 for	 the	 generation	 of	
PDX	models,	provide	a	summary	of	presently	available	collections	of	these	models,	list	
current	 applications	 and	 major	 contributions	 of	 PDX	models	 to	 cancer	 therapeutics	
and	personalized	medicine,	and	highlight	important	issues	for	the	future	development	
of	 this	approach.	Finally,	we	 introduce	a	European	 initiative	aimed	at	establishing	an	
academic	consortium	of	laboratories	having	established	collections	of	PDX	models	with	
the	goal	of	 triggering	scientific	collaboration,	conducting	multicenter	preclinical	 trials	
and	developing	new	models.	As	studies	demonstrate	the	significant	heterogeneity	of	
human	cancer,	large	collections	of	PDX	models,	not	affordable	by	individual	groups	but	
through	 the	 set	 up	 of	 collaborative	 networks,	 are	 key	 to	 tackle	 the	 challenge	 of	
precision	medicine.	
	
	
	
METHODOLOGICAL	ASPECTS	
	
The	process	of	generating	PDX	models	in	mice	from	fresh	primary	or	metastatic	human	
cancer	is	extensively	described	in	the	literature	(10,	13).		While	individual	groups	have	
developed	specific	methodological	approaches,	the	fundamentals	are	common.	Table	
1	provides	a	summary	of	approaches	used	to	generate	the	most	comprehensive	PDX	
collections	 currently	 available.	 	 Briefly,	 pieces	 of	 primary	 or	metastatic	 solid	 tumors	
maintained	as	 tissue	 structures	are	collected	by	 surgery	or	biopsy	procedures.	 Some	
studies	 have	 also	 used	 fluid	 drained	 from	 malignant	 ascites	 or	 pleural	 effusions.		
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Tumors	 are	 implanted	 as	 pieces	 or	 single	 cell	 suspensions,	 either	 alone	 or	 in	 some	
studies	 coated	with	matrigel	or	mixed	with	human	 fibroblasts	or	mesenchymal	 stem	
cells.	 	 The	 most	 common	 site	 of	 implantation	 is	 on	 the	 dorsal	 region	 of	 mice	
(subcutaneous	implantation),	although	implantation	in	the	same	organ	as	the	original	
tumor	 may	 be	 an	 option	 (orthotopic	 implantation,	 i.e.	 pancreas,	 oral	 cavity,	 ovary,	
mammary	fat	pad,	brain,	etc.).	In	addition,	independently	of	the	tumor	origin,	several	
approaches	 have	 implanted	 primary	 tumors	 in	 the	 renal	 capsule	 in	 an	 effort	 to	
increase	 engraftment	 success	 rates.	 A	 variety	 of	 mouse	 strains	 having	 different	
degrees	of	immunosuppression	have	been	used	in	these	studies.	Supplementary	Table	
1	lists	the	principal	characteristics	of	the	most	commonly	used	mouse	strains	including	
their	 level	 of	 immune	 suppression	 as	 well	 as	 advantages	 or	 disadvantages.	 For	
hormone	 sensitive	 tumors,	 some	 studies	 have	 used	 hormone	 supplementation	with	
the	intent	of	increasing	engraftment	rates.			
	
Some	approaches	may	have	theoretical	advantages	with	regard	to	higher	and	
faster	 engraftment	 rates	 and	 generation	 of	 models	 that	 better	 recapitulate	 human	
tumors	and	are,	therefore,	more	predictive.	However,	it	is	important	to	mention	that	
very	few	studies	have	properly	addressed	comparative	implantation	methods	for	these	
endpoints.	 	 Studies	 in	which	 PDX	models	 have	 been	 generated	 simultaneously	 from	
primary	 tumors	 and	 metastatic	 lesions	 suggest	 that	 metastases	 have	 a	 higher	
engraftment	 rate	 (14,	 15).	 Defining	 the	 most	 appropriate	 host	 mouse	 strains	 to	
generate	PDX	models	is	an	important	consideration.	It	is	assumed	that	more	severely	
immunosuppressed	 models	 such	 as	 non-obese	 diabetic/severe	 combined	
immunodeficiency	disorder	(NOD/SCID)	or	NOD/SCID/IL2λ-receptor	null	(NSG)	models	
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are	better	suited	for	PDX	generation	due	to	higher	engraftment	rates.	 	 Indeed,	these	
are	 the	preferred	 rodent	 strains	 for	many	groups.	However,	 in	human	breast	 cancer	
(HBC)	where	this	question	has	been	robustly	 interrogated,	 implantation	 in	NOD/SCID	
versus	NSG	mice	yielded	similar	take	rates	(16).	In	addition,	host	supplementation	with	
estradiol	pellets	increased	engraftment	rates	from	2.6	to	21.4	%	while,	for	reasons	that	
are	 unclear,	 co-implantation	 with	 immortalized	 human	 fibroblasts	 decreased	
engraftment	rate	(16).		In	contrast,	in	another	study,	a	mixture	of	irradiated	and	non-
irradiated	 human	 fibroblasts	 provided	 improved	 results	 (17).	 Likewise	 orthotopic	
tumor	 implantation	 ("orthoxenografts",	 (18))	 may	 also	 confer	 a	 translational	
advantage,	 as	 the	 tumor	 develops	 in	 the	 same	 anatomical	 microenvironment.	
Generation	 of	 orthoxenografts	 is	 more	 labor-intensive,	 requires	 complex	 surgery,	 is	
more	 expensive	 and	 often	 requires	 imaging	 methods	 to	 monitor	 tumor	 growth.		
However,	 for	 several	 tumor	 types	 (e.g.	ovarian	cancer	or	 lung	cancer),	 this	approach	
substantially	 increases	tumor	take	rates	(19).	 	 In	this	vein,	orthotopic	 implantation	 in	
the	 testis	 is	 essential	 for	 the	 growth	 of	 testicular	 germ	 cell	 tumors.	 As	 for	 tumor	
implantation	 in	 the	 renal	 capsule,	 it	 yielded	an	 impressive	90	%	engraftment	 rate	 in	
non-small	 cell	 lung	 cancer	 (NSCLC)	 as	 compared	 to	 25%	 following	 subcutaneous	
implantation,	 although	 these	 results	 were	 not	 obtained	 from	 a	 single	 comparative	
study	 (20,	 21).	 Furthermore,	 renal	 cell	 capsule	 implantation	 shortens	 time	 to	
engraftment,	 which	 is	 one	 of	 the	 most	 important	 variables	 for	 studies	 seeking	 to	
implement	real	time	PDX	data	for	personalized	cancer	treatment	(20).	
	
SALIENT	FEATURES	OF	PDX	MODELS	
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As	mentioned,	 the	 principal	 limitation	 of	 conventional	 pre-clinical	models	 (“in	 vitro“	
cell	 line	studies	as	well	as	 “in	vivo“	xenograft	models	generated	by	 implanting	 these	
cells	 in	 immunodeficient	 mice)	 is	 their	 poor	 predictive	 value	 with	 regard	 to	 clinical	
outcome	(4).		The	reasons	why	conventional	cancer	models	have	such	poor	predictive	
power	are	not	completely	understood.		However,	variations	in	the	basic	biology	of	the	
models	 as	 they	 evolve	 are	 likely	 a	 key	 factor.	 	 The	 process	 of	 adaptation	 to	 in	 vitro	
growth	 conditions	 leads	 to	 changes	 in	 the	 biological	 circuits	 of	 the	 cancer	 cell	 that	
differ	from	the	host	derived	entity.		These	include	modifications	in	key	properties	such	
as	 genetic	 content,	 invasive	 capabilities,	 maintenance	 of	 a	 heterogeneous	 cell	
population	and	the	reliance	on	specific	growth	and	survival	pathways	(6).			
	
The	rationale	for	developing	PDX	models	is	based	on	the	expectation	that	these	
models	will	represent	enhanced	preclinical	tools	and	will	be	more	predictive	of	human	
cancer	biology	and	patient	response	to	treatments.		In	addition,	PDX	models	offer	the	
potential	for	personalizing	patient	cancer	treatment.		Proving	the	value	of	PDX	models	
may	be	approached	from	different	perspectives:	one	such	approach	is	to	compare	the	
histopathological,	biological	and	genetic	features	of	a	PDX	model	with	its	donor	tumor	
(also	called	‘validation’).	The	underlying	hypothesis	is	that	PDX	models	will	retain	key	
characteristics	 of	 the	 donor	 tumor	 and	 that	 these	 characteristics	will	 be	maintained	
through	 successive	mouse-to-mouse	 passages	 in	 vivo.	 Table	 2	 summarizes	 the	 data	
from	 different	 studies	 in	 which	 PDX	models	 have	 been	 compared	 to	 donor	 tumors	
using	a	variety	of	methods.		In	general,	these	studies	show	that	PDX	models	retain	the	
principal	 characteristics	 of	 donor	 tumors,	 including	 fine	 tissue	 structure	 and	 subtle	
microscopic	details	such	as	gland	architecture,	mucin	production	or	cyst	development.		
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At	the	biological	level,	most	studies	also	show	good	concordance	between	tumors	and	
the	models	derived	from	them.		Analysis	of	gene	expression	profiles	shows	that	there	
are	no	substantial	 changes	between	donor	 tumor	and	 their	corresponding	PDX,	with	
only	 genes	 involved	 in	 the	 stromal	 compartment	 and	 immune	 function	 being	 less	
represented	 in	 models,	 due	 to	 the	 replacement	 of	 the	 human	 stroma	 by	 murine	
elements.		Indeed,	using	unsupervised	clustering	analysis,	paired	donor	tumor	and	PDX	
model	 cluster	 together	 in	most	of	 the	 studies.	 	Analyses	of	 copy	number	alterations	
(CNAs)	 and	 exome	 sequencing	 data	 also	 show	 extraordinary	 concordance	 between	
paired	samples,	with	a	 trend	towards	higher	 frequency	of	genomic	alterations	 in	 the	
PDX	model	likely	as	a	result	of	increased	human	tumor	DNA	purity	in	the	PDX	model.	
Indeed	in	PDX,	the	cross-contamination	by	normal	DNA	from	the	human	stromal	tissue	
is	avoided.		A	recent	study	reports	whole	genome	sequencing	of	several	trios	(primary	
tumors,	 lymphocytes	 and	 PDX)	 in	 breast	 cancer,	 showing	 that	 PDX	 have	 relatively	
stable	genomes	without	a	significant	accumulation	of	DNA	structural	rearrangements	
but	with	some	enrichment	for	PDX-unique	single-nucleotide	variants	(22).		These	PDX-
unique	 mutations	 could	 be	 the	 result	 of	 adaption	 to	 transplantation	 into	 the	 new	
microenvironment,	but	could	also	be	present	 in	 the	original	 tumor	below	detectable	
limits.	A	study	showed	that	many	CNA	changes	found	 in	sarcoma	PDX	are	frequently	
observed	in	sarcoma	patients,	suggesting	that	xenografts	may	in	some	way	represent	
the	 genomic	 rearrangement	 intrinsic	 to	 tumor	 progression	 (23).	 This	 was	 also	
suggested	 in	 another	 study	 describing	 that	 many	 of	 the	 mutations	 detected	 in	 the	
breast	 PDX	 were	 also	 observed	 in	 brain	 metastases	 derived	 from	 the	 same	 patient	
(24).	 Furthermore,	 mouse-to-mouse	 propagation	 does	 not	 substantially	 change	 the	
functional	 characteristics	 of	 the	 grafted	 tumor.	 	 Studies	 that	 have	 compared	 the	
	 12	
response	to	drug	treatments	of	PDX	models	from	different	passages	(up	to	ten)	show	
stable	response	rates	across	generations,	further	supporting	the	phenotypic	stability	of	
these	models	(25,	26).	In	contrast,	an	interesting	study	compared	the	gene	expression	
profiles	of	a	donor	tumor	with	those	of	PDX	models	and	cell	lines	developed	from	that	
tumor,	both	in	vitro	and	in	vivo	in	conventional	xenograft	models.		The	data	show	that	
while	 the	gene	expression	profile	of	PDX	models	 is	 similar	 to	 the	original	 tumor,	cell	
lines	developed	from	the	same	specimen	display	a	different	expression	profile	that	is	
not	restored	by	in	vivo	subcutaneous	propagation	in	mice	(27).			
	
An	additional	way	to	examine	model	fidelity	as	compared	to	the	original	tumor	
is	 to	 focus	 on	 well-known	 disease-based	 genomic	 alterations	 rather	 than	 directly	
comparing	 individual	 donor	 versus	 PDX	 characteristics.	 	 In	 PDX	models	 of	 squamous	
cell	carcinoma	of	the	head	and	neck	(SCCHN)	for	example,	the	prevalence	of	TP53	and	
NOTCH	mutations	 is	 similar	 to	 those	 reported	 in	human	 tumors	 (25).	 	 Similar	 results	
have	been	observed	in	colorectal	cancer	(CRC)	and	pancreatic	cancer	(PDAC)	models	in	
which	 the	 frequency	 of	mutations	 in	 genes	 such	 as	TP53	 or	 RAS	 closely	mirrors	 the	
frequency	 of	 these	 mutations	 in	 human	 samples	 (26,	 28,	 29).	 In	 HBC	 PDX	 models,	
several	studies	using	gene	expression	profiles	have	shown	that	intrinsic	breast	cancer	
phenotypes	are	well	represented	and	in	concordance	with	the	original	tumors	(16,	30,	
31).	 Nevertheless	 ER+	 subtypes	 are	 under-represented,	 in	 particular	 the	 recently	
described	 ER+	 subtypes	 with	 good	 prognosis.	 Furthermore,	 when	 examining	
metabolism,	the	metabolic	profiles	as	detected	by	high	resolution	magic	angel	spinning	
MR	spectroscopy	are	remarkably	similar	when	comparing	patient	material	and	tissue	
from	orthotopically	growing	basal-like	and	luminal-like	breast	cancer	(32).	
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A	 complementary	 approach	 to	 determine	 the	 value	 of	 PDX	models	 in	 cancer	
research	 (discussed	and	 illustrated	below)	 is	by	analyzing	 the	predictive	value	of	 the	
data	obtained	from	PDX	studies	with	regards	to	drug	efficacy,	biomarker	analysis,	and	
patient	outcome.	 In	this	sense,	a	similar	 level	of	activity	as	observed	 in	the	clinic	has	
consistently	been	shown	in	studies	in	which	clinically	applied	drugs	or	regimens	have	
been	 tested	 in	 PDX	 models.	 Table	 3	 provides	 a	 summary	 of	 studies	 in	 which	 PDX	
models	from	different	cancer	types	have	been	treated	with	agents	used	in	the	clinical	
care	of	these	patients.		While	the	analysis	of	data	is	complicated	by	different	response	
criteria	used,	 in	general	 there	 is	 remarkable	similarity	between	the	activity	of	agents	
such	 as	 cetuximab	 in	 CRC	 models	 and	 gemcitabine	 in	 PDAC	 models	 and	 respective	
clinical	trial	data	(28,	29,	33).	Of	even	greater	relevance	is	the	remarkable	one	to	one	
concordance	 in	 studies	 that	 compare	 the	 individual	 donor	 patient	 response	 to	
conventional	anticancer	agents	with	that	of	his/her	PDX	(16,	21,	33,	34).		Furthermore,	
analysis	 of	 clinically	 validated	 biomarkers	 such	 as	KRAS	mutations	 and	 resistance	 to	
EGFR	 inhibitors	 in	 PDX	 studies	 reached	 the	 same	 conclusions	 as	 clinical	 trials,	 as	
discussed	 in	more	detail	below	(28).	Finally,	emerging	studies	 in	which	patients	have	
been	treated	with	drugs	selected	for	their	activity	against	their	PDX	counterparts	show	
a	high	predictive	power,	 further	 supporting	 the	notion	 that	 response	 in	PDX	models	
correlates	with	clinical	outcome	(35).	
	
APPLICATIONS	OF	PDX	MODELS	IN	CANCER	RESEARCH	
	
Drug	Screening	and	Biomarker	Development.	
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It	is	well	known	that	one	of	the	major	issues	in	oncology	drug	development	is	the	low	
success	 rate	 of	 new	 agents	 (36).	 Many	 compounds	 are	 advanced	 to	 large	 phase	 III	
studies,	which	consume	considerable	resources,	to	end	up	failing	because	of	a	lack	of	
efficacy.	 	 Part	 of	 the	 reason	 for	 these	 poor	 results	 is	 that	 conventional	 preclinical	
models	 utilized	 to	 screen	 new	 agents	 for	 clinical	 development	 have	 poor	 predictive	
value	(4).	In	addition,	new	drugs	were	tested	but	biomarkers	for	these	particular	drugs	
were	not	 included	 in	 these	 studies	 in	 the	absence	of	 suitable	biomarkers	 for	patient	
selection	and	response	monitoring.	Thus,	strategies	to	diminish	this	high	attrition	rate	
are	needed.	 	 In	 this	 regard,	 the	availability	of	preclinical	models	with	high	predictive	
value	is	of	major	interest,	as	it	will	permit	the	conduction	of	preclinical	phase	II	studies	
to	select	potential	indications	for	subsequent	clinical	trials.			
	
		The	rationale	for	implementing	PDX	models	to	achieve	this	objective	relies	on	
the	fact	that	these	models	are	predictive	of	clinical	outcome.		This	has	been	shown	in	
several	retrospective	studies	and	more	recently	in	prospective	clinical	trials.		As	listed	
in	Table	3,	a	number	of	reports	in	CRC,	NSCLC,	SCCHN,	HBC	and	renal	cell	cancer	(RCC)	
have	tested	the	response	rate	of	drugs	used	as	standard	of	care	in	medical	oncology	in	
PDX	models.		These	experiments	show	that	the	response	rates	in	PDX	models	correlate	
with	 those	observed	 in	 the	clinic,	both	 for	 targeted	agents	and	 for	classic	cytotoxics.		
For	 example,	 an	 extensive	 analysis	 of	 the	 EGF	 receptor	 inhibitor	 cetuximab	 in	 47	
unselected	CRC	PDX	models	showed	a	10.6	%	response	rate,	which	is	identical	to	the	
response	rate	observed	with	this	agent	in	patients	with	this	disease	(28).		Similar	data	
have	 been	 also	 published	 for	 SCCHN,	 the	 other	 indication	 in	 which	 cetuximab	 is	
commonly	used	(25).	MEK	and	PI3K/mTOR	inhibitors	proved	to	be	poorly	effective	in	a	
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panel	of	40	KRAS	mutant	CRC	PDX	models,	again	in	accordance	with	clinical	data	from	
phase	 I	 trials	 (37).	 In	 RCC,	 PDX	 models	 showed	 response	 to	 the	 mTOR	 inhibitor	
sirolimus	and	the	angiogenesis	inhibitors	sunitinib	and	dovitinib,	but	not	to	erlotinib	as	
was	also	observed	in	clinical	trials	(15).	 	With	regards	to	conventional	chemotherapy,	
studies	 in	NSCLC,	HBC,	CRC	and	PDAC	demonstrated	 that	 response	 rates	 to	clinically	
used	agents	such	as	paclitaxel,	carboplatin,	gemcitabine,	5-fluorouracil,	irinotecan	and	
adriamycin,	 among	 others,	 are	 comparable	 between	 PDX	 models	 and	 clinical	 data	
(Table	3).			
	
More	 recently,	 the	 role	 of	 PDX	 models	 as	 potential	 screening	 platforms	 for	
clinical	trials	has	been	also	shown	in	a	prospective	study	in	PDAC.		This	work	showed	
that	the	combination	of	nab-paclitaxel	and	gemcitabine	 is	effective	 in	PDX	models	of	
PDAC,	a	finding	that	correlated	with	the	clinical	efficacy	of	this	combination.	 	 In	fact,	
this	regimen	has	recently	been	demonstrated	to	provide	a	survival	benefit	for	patients	
with	 advanced	 PDAC	 in	 a	 randomized	 phase	 III	 study,	 and	 is	 likely	 to	 become	 a	
standard	of	care	in	this	setting	(38).	Likewise,	failure	to	exert	antitumor	efficacy	in	PDX	
models	 correlates	with	negative	 clinical	 results.	This	 is	 illustrated	 in	PDAC	 for	agents	
such	as	the	Src	inhibitor	saracatinib	and	the	mTOR	inhibitor	sirolimus,	for	which	lack	of	
efficacy	in	unselected	PDX	preclinical	studies	predicted	failure	of	the	same	strategy	in	
the	clinic	(39,	40).	Based	on	these	data,	PDX	models	have	now	become	an	integral	part	
of	the	preclinical	screening	of	new	anticancer	agents.			
	
One	 critical	 aspect	 of	 large	 preclinical	 studies	 in	 PDX	models	 is	 that	 they	 not	
only	 help	 to	 prioritize	 potential	 clinical	 indications,	 but	 they	 may	 also	 facilitate	 the	
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identification	 of	 potential	 drug	 efficacy	 biomarkers.	 The	 concordance	 between	 PDX	
models	 and	 human	 trials	 with	 regard	 to	 biomarkers	 of	 drug	 susceptibility	 and	 drug	
resistance	is	indeed	notable.	In	CRC	for	example,	it	has	been	clearly	shown	in	a	number	
of	studies	that	KRAS	mutant	PDX	models	do	not	respond	to	cetuximab.	KRAS	wild-type	
status	is	now	a	well-documented	clinical	biomarker	for	this	targeted	therapy	(28,	29).		
Similar	 data	 were	 observed	 in	 NSCLC	 (21).	 In	 fact,	 it	 could	 be	 argued	 that	 if	 these	
preclinical	studies	had	been	conducted	prior	or	in	parallel	to	the	clinical	development	
of	cetuximab,	the	discovery,	validation	and	approval	of	KRAS	mutation	as	a	marker	of	
resistance	 would	 have	 been	 expedited.	 In	 PDAC,	 PDX	 studies	 with	 gemcitabine	
identified	expression	of	 the	gemcitabine	activating	enzyme	deoxycytidine	kinase	as	a	
predictor	 of	 drug	 efficacy.	 A	 subsequent	 analysis	 of	 this	 marker	 in	 clinical	 samples	
confirmed	 these	 results	 (26,	 41).	 Likewise,	 PDX	 models	 have	 been	 used	 to	 identify	
metabolic	as	well	as	imaging	biomarkers	(42,	43).	
	
Equally	 important	 is	 the	 discovery	 of	 resistance	 biomarkers	 that	may	 help	 to	
design	 combination	 clinical	 trials.	 In	CRC	 it	 has	been	 shown	 that	 tumors	 resistant	 to	
EGFR	inhibition	harbor	amplifications	of	other	genes	such	as	HER2	and	MET	 (28,	44).	
Preclinical	 combination	 studies	with	 agents	 targeting	 these	 genes	 showed	promising	
preclinical	 efficacy	 resulting	 in	 clinical	 translation.	 Likewise,	 in	 SCCHN,	 activating	
mutations	 in	 the	 PIK3CA	 gene	 confer	 resistance	 to	 EGFR	 inhibitors	 that	 can	 be	
modulated	by	agents	that	inhibit	the	PI3K	pathway	(25).		PDX	models	are	also	versatile	
tools	 for	 simulating	 resistance	 when	 exposed	 to	 treatment	 strategies	 used	 in	 the	
clinical	setting.	This	has	been	shown	for	example	in	ovarian	cancer,	in	which	prolonged	
exposure	 to	 cisplatin	 results	 in	 induction	 of	 resistance	 to	 this	 agent	 in	 a	 platinum-
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sensitive	model,	similar	to	what	is	observed	in	the	clinical	setting.		This	model	has	been	
used	 to	 explore	 new	 agents,	 with	 a	 goal	 to	 select	 drugs	 to	 be	 tested	 in	 platinum-
resistant	 patients	 such	 as	 the	 DNA	 minor	 groove	 binder	 lurbinectedin	 (18).	
Interestingly,	 cisplatin-sensitive	 and	 -resistant	 ovarian	 orthoxenografts	 recapitulate	
characteristic	 features	 of	 primary	 human	 tumor	 response,	 such	 as	 the	
histopathological	tumor	regression	criteria	associated	with	patient	treatment	response	
(36).	 Resistance	 to	 targeted	 drugs,	 such	 as	 vemurafenib,	 has	 been	 induced	 in	
melanoma	PDX	models.	Not	only	a	mechanism	of	resistance	was	identified,	but	also	a	
novel	drug	administration	strategy	applicable	to	the	clinic	was	proposed	to	overcome	
resistance	that	is	clinically	applicable	has	been	identified	(45).	Until	now,	no	published	
work	 compared	 PDX	models	 established	 from	primary	 and	 recurrent	 tumor	 samples	
from	the	same	patient.			
	
Preclinical	testing	in	PDX	models	can	also	facilitate	optimization	of	clinical	trial	
design.	 	 This	 is	 perhaps	 best	 illustrated	 in	 studies	 with	 cancer	 stem	 cell	 (CSC)	
therapeutics	such	as	inhibitors	of	the	Sonic	Hedgehog,	Nodal/Activin,	TGFβ	and	Notch	
pathways	 (46-49).	 In	 PDX	 studies,	 these	 agents	 failed	 to	 induce	 synergistic	 tumor	
regression	 responses	 when	 combined	 with	 chemotherapy	 but	 resulted	 in	 tumor	
growth	 delay	 and,	 importantly,	 in	 a	 decrease	 in	 tumor	 initiation	 and	 relapse.	 In	
addition,	 in	 re-implantation	 studies,	 it	 was	 shown	 that	 administration	 of	 an	 agent	
directed	 at	 CSCs	 prevented	 re-engraftment	 of	 treated	 tumors	 when	 excised	 and	
reinjected	in	host	mice	(49).		The	use	of	PDX	models	in	this	context	is	crucial	to	assess	
and	understand	the	effect	of	pharmacological	compounds	on	CSCs.	These	findings	may	
have	further	implications	for	clinical	trial	design,	as	it	would	suggest	that	treatment	of	
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minimal	residual	disease	(such	as	during	the	postoperative	period,	or	after	debulking	
chemotherapy)	and	using	a	time	to	event	endpoint,	may	be	an	appropriate	setting	in	
which	to	apply	this	approach.	
	
Based	on	these	data,	PDX	models	may	play	an	important	role	in	drug-response	
studies	 to	 help	 select	 populations	 of	 patients	 most	 likely	 to	 be	 sensitive	 to	 a	 new	
agent,	as	well	as	to	prioritize	the	development	of	new	biomarkers.		Figure	1	depicts	a	
proposed	path	 for	 integration	of	PDX	models	 in	new	drug	development.	 	 For	agents	
that	are	selected	for	clinical	studies	we	propose	to	perform	PDX	testing	in	parallel	to	
phase	I	safety	and	pharmacological	studies.		PDX	preclinical	testing	should	be	done	in	
tumor	types	of	 interest	selected	by	prior	preclinical	data	both	with	regard	to	disease	
type	but	also	in	molecularly	defined	groups	as	in	basket-type	trials.		Indeed,	one	of	the	
advantages	 of	 the	 existing	 PDX	model	 collections	 is	 that	 they	have	been	extensively	
characterized	at	the	histological,	molecular	and	genomic	level.	 	 	Based	on	the	type	of	
agent,	 studies	 can	 be	 adapted	 to	 test	 single	 agents	 or	 clinically	 meaningful	
combinations,	 using	 appropriate	 endpoints	 such	 as	 response	 rate	 (short-response	
assay)	or	 tumor	growth	delay	 (long-term	response).	Agents	 showing	activity	 in	 initial	
screens	 can	 be	 further	 studied	 in	 a	 larger	 group	 of	 models	 using	 statistical	
methodologies	similar	to	two-stage	clinical	trial	design.		Once	again,	the	availability	of	
a	 larger	 collection	 of	 models	 through	 the	 collaboration	 of	 academic	 and	 non-profit	
organizations	would	enable	these	 larger	screens.	 	Biological	and	genetic	comparisons	
between	 sensitive	 and	 resistant	 models	 can	 be	 explored	 for	 the	 prioritization	 of	
biomarkers	for	inclusion	in	clinical	studies.		
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Co-clinical	Trials.	
Once	 a	 drug	 enters	 clinical	 trials	 there	 are	 limited	 opportunities	 to,	 on	 a	 real-time	
basis,	 analyze	 and	 integrate	 information	 that	may	 be	 useful	 for	 the	 development	 of	
that	agent	(50).		Even	in	studies	that	select	patients	based	on	molecular	abnormalities	
and	 that	 incorporate	 tumor	 tissue,	 normal	 tissue	 and	 imaging-based	
pharmacodynamic	 endpoints,	 there	 are	 few	 options	 for	 real-time	 integration	 and	
exploitation	of	the	observed	information	in	the	trial.		This	is	in	part	due	to	the	intrinsic	
nature	of	clinical	trials	in	which	patients	are	treated	with	one	drug	or	regimen	at	a	time	
and	 followed	under	very	 specific	 criteria,	but	also	 to	 the	 lack	of	 sufficient	and	easily	
accessible	materials	for	more	in	depth	studies	of	clinical	observations.		Thus,	patients	
may	develop	extreme	responses	or	rapid	resistance	but	it	is	in	general	difficult	to	study	
the	underlying	mechanisms	in	detail.	
	
To	 solve	 some	 of	 these	 issues,	 the	 concept	 of	 co-clinical	 trials	 has	 been	
proposed.	 	 In	 their	original	 format,	 these	 studies	 refer	 to	 the	use	of	GEM	models	of	
cancer	to	determine	patient	selection	strategies	as	well	as	to	discover	mechanisms	of	
resistance	 to	 treatment	 approaches	 (51,	 52).	 PDX	 models	 have	 been	 used	 in	 this	
context	in	parallel	studies	in	rodent	models	and	patients,	and	have	indeed	been	useful	
in	identifying	potential	biomarkers	(39,	53).		Moreover,	PDX	models	may	also	be	used	
in	another	application	of	 the	 co-clinical	 trial	 concept,	 as	depicted	 in	Figure	2.	 In	 this	
approach,	 a	 personalized	 PDX	model,	 so-called	 ‘Avatar’	model,	 is	 developed	 from	 a	
patient	 enrolled	 in	 a	 clinical	 trial	 and	 treated	with	 the	 same	experimental	 agents	 to	
emulate	 clinical	 response.	 	 This	 strategy	 permits	 assessment	 of	 drug	 response	
simultaneously	 in	the	patient	and	mouse	model,	providing	an	 interesting	platform	to	
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investigate	 biomarkers	 of	 susceptibility	 and	 resistance,	 as	 well	 as	 interrogation	 of	
novel	combination	strategies	to	overcome	emergent	resistance	pathways.	
	
Personalized	Medicine.	
The	 field	 of	 oncology	 is	 rapidly	 evolving	 from	 an	 ‘all	 comers’	 approach	 to	 cancer	
therapy	to	an	era	in	which	patient’s	tumors	are	profiled	in	greater	detail	to	select	the	
most	appropriate	treatment	(54).		CRC,	NSCLC	and	HBC	tumors	to	name	a	few,	are	now	
routinely	profiled	to	aid	in	the	treatment	decision-making	process	(55).		Furthermore,	
cell	free	circulating	tumor	DNA	is	now	also	analyzed	to	direct	patients	to	appropriate	
clinical	 trials	 with	 molecularly	 targeted	 agents	 (56).	 While	 this	 tailored	 strategy	
represents	a	significant	advance	in	translational	cancer	research,	further	advances	are	
required.		One	such	outstanding	advance	requires	consideration	of	patients	for	whom	
despite	extensive	testing,	no	biomarkers	of	drug	efficacy	are	detected.		These	patients	
cannot	 have	 their	 treatment	 personalized.	 The	 opposite	 situation	 is	 also	 true:	 as	
cancer	profiling	evolves	and	becomes	more	comprehensive,	multiple	potential	targets	
are	identified	in	some	patients	confounding	the	selection	of	the	most	appropriate	one.	
	
Avatar	mouse	models	have	been	used	to	personalize	cancer	treatment	(57).	Interest	in	
using	 these	models	 emerges	 from	 studies	 such	 as	 those	 listed	 in	 Table	 3	 that	 have	
demonstrated	 a	 remarkable	 correlation	 between	 drug	 response	 in	 PDX	models	 and	
clinical	 response.	 In	 NSCLC	 for	 example,	 PDX	 models	 have	 been	 used	 to	 test	 the	
efficacy	of	three	of	the	most	commonly	used	first-line	chemotherapy	regimens	in	this	
setting.		The	results	of	this	study	show	that	approximately	two	thirds	of	NSCLC	patients	
is	 sensitive	 to	 first-line	 chemotherapy	 while	 one	 third	 is	 resistant.	 Interestingly,	
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patients	 are	not	 sensitive	 to	 all	 regimens	equally	 and	 some	patients	 are	 sensitive	 to	
one	but	resistant	to	another,	suggesting	that	there	is	potential	to	personalize	regimen	
selection	(20).		In	another	study,	investigators	used	Avatar	models	from	patients	with	
advanced	 cancer	 to	 screen	 a	 large	 battery	 of	 anticancer	 agents	 and	 select	 the	most	
effective	agent	to	treat	the	donor	patient.		The	results	of	this	trial	show	that	when	all	
factors	 involved	 are	 correctly	 aligned,	 the	 response	 in	Avatars	 and	patients	 is	 highly	
correlated.		However,	in	most	patients	the	approach	is	not	feasible	for	reasons	such	as	
failure	of	the	tumor	to	engraft,	lack	of	effective	agents,	and	length	of	time	required	for	
a	 complete	 study	 (33,	 35).	 Thus,	 strategies	 to	 optimize	 these	 issues,	 as	 discussed	
below,	are	needed.			
	
It	is	likely	that	the	contribution	of	PDX	models	to	personalized	cancer	treatment	
will	increase	by	their	integration	in	more	global	personalized	medicine	approaches	like	
the	one	represented	in	Figure	3,	rather	than	as	a	stand-alone	platform.		The	significant	
revolution	 in	 cancer	 genetics	 is	 permitting,	 for	 the	 first	 time,	 the	 gathering	 of	
enormous	 amounts	 of	 genomic	 information,	 including	 assessment	 of	 a	 complete	
cancer	genome,	to	aid	in	clinical	decision-making	(55,	58).	In	many	oncology	clinics,	it	is	
now	becoming	common	practice	to	analyze	a	set	of	50-100	relevant	cancer	genes	for	
hundreds	of	mutations.	From	this	approach,	numerous	potential	targets	have	emerged	
for	individual	patients	that	may	potentially	be	linked	to	clinical	response.	 	 In	addition	
to	bioinformatics	and	 in	silico	prediction	data	from	cancer	cell	 line	data,	personalized	
PDX	models	may	now	be	useful	 in	 this	 setting	 as	 they	 facilitate	 testing	of	 candidate	
regimens	 in	 the	 patient's	 own	 tumor	 to	 select	 for	 the	 most	 efficacious	 treatment	
approach	(3,	59).		Furthermore,	the	integration	of	observed	responses	in	mice	with	the	
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tumor	genetic	information	would	eventually	lead	to	the	discovery	of	new	biomarkers	
of	drug	efficacy.		For	patients	whose	tumors	do	not	take	in	mice	or	those	that	require	a	
long	 time	 to	 be	 established	 and	 characterized,	 an	 alternative	 to	 the	 Avatar	 strategy	
could	 be	 to	 orientate	 treatment	 choice	 based	 on	 drug	 response	 of	 a	 similar	 PDX.	
Primary	 tumors	 or	 metastases	 biopsies	 would	 be	 molecularly	 characterized	 and	
compared	to	available	PDX	collections	from	the	same	pathology,	for	which	responses	
to	 chemotherapies	 and	 targeted	 agents	 have	 been	 previously	 determined	
(Supplementary	Figure	1).	
	
	
LIMITATIONS	OF	PDX	MODELS	
	
While	the	incorporation	of	PDX	models	in	cancer	research	brings	some	improvements	
as	detailed	above,	it	is	clear	that	they	still	have	important	limitations	that	need	to	be	
addressed	 to	 improve	 their	 use	 in	 translational	 cancer	 research.	 	 Some	 of	 these	
limitations	are	technical	in	nature	and	include	several	issues,	such	as	(i)	consideration	
of	 the	 most	 appropriate	 tissue	 from	 which	 to	 generate	 a	 PDX	 model	 and	 the	
processing	 of	 this	 tissue.	 Most	 of	 the	 published	 studies	 have	 relied	 on	 surgical	
specimens	 that	 naturally	 provide	 large	 quantities	 of	 tissues.	 While	 this	 approach	 is	
useful	 to	 generate	 PDX	 collections,	 smaller	 samples,	 such	 as	 tumor	 biopsies	 or	 fine	
needle	 aspirations	 are	 better	 suited	 for	 personalized	medicine	 applications.	 (ii)	 It	 is	
important	 to	 define	 the	 best	 strategy	 of	 engraftment	 in	 mice	 (subcutaneous	 vs.	
orthotopic	 implantation)	 for	 different	 tumor	 types.	 (iii)	 Delay	 between	 engraftment	
time	in	mice	and	clinical	schedules	for	patients’	treatment	is	also	a	limiting	factor	for	
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real-time	personalized	medicine	applications.	It	normally	takes	4-8	months	to	develop	
a	 PDX	model	 ready	 for	 a	 preclinical	 study,	 a	 time	 frame	 that	many	 patients	 do	 not	
have.	 (iv)	 Another	 problem	 is	 engraftment	 failure	which	 is	 still	 high	 for	 some	 tumor	
types	 with	 particular	 phenotypes,	 such	 as	 hormone	 receptor	 positive	 HBC.	 	 For	
personalized	medicine	 strategies	 it	 is	mandatory	 to	 improve	 tumor	 take	 rates	 to	 an	
acceptable	60-70%,	this	being	one	of	the	main	aspects	requiring	improvement.		This	is	
not	only	 a	problem	 in	personalized	medicine,	 as	most	patients	do	not	have	a	 linked	
PDX	model,	but	also	 in	drug	screening	studies	as	current	PDX	collections	are	skewed	
towards	 certain	 cancer	 subtypes	 and	 do	 not	 broadly	 represent	 the	 disease	
heterogeneity.			
	
One	key	aspect	in	PDX	research	is	the	need	to	use	immunodeficient	host	strains	
for	tumor	engraftment	and	propagation.	 	These	mice	 lack	functional	elements	of	the	
immune	system	(Table	2)	to	avoid	rejection	of	foreign	tissues	and	permit	engraftment	
of	 the	 tumor.	 	 For	 this	 reason,	 PDX	models	 are	 of	 limited	 use	 in	 screening	 immune	
mediating	agents	such	as	vaccines,	immune	modulators	(e.g.	anti-PD1)	or	agents	that	
function	by	activating	immune	elements	such	as	anti-CD40	antibodies.			
	
Another	 critical	 aspect	 is	 the	 substitution	of	 human	 tumor	by	murine	 stroma	
throughout	tumor	growth	in	mice.	 	 In	different	studies	 in	which	this	aspect	has	been	
addressed,	 it	has	been	consistently	shown	that	the	human	cancer	stroma	included	in	
the	 tumor	 pieces	 implanted	 is	 rapidly	 replaced	 by	murine	 stroma,	 so	 that	 after	 3-5	
passages	when	the	models	can	be	used	for	drug	testing,	stroma	is	in	essence	murine.		
This	includes	the	extracellular	matrix,	cancer	associated	fibroblasts,	blood	vessels	and	
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inflammatory	and	immune	mediating	cells	such	as	leukocytes	and	macrophages.		This	
new	murine	stroma	probably	results	in	changes	in	paracrine	regulation	of	the	tumor	as	
well	as	 in	physical	properties	such	as	 interstitial	pressure,	that	may	limit	the	study	of	
agents	directed	against	this	tumor	compartment	(50,	60).	
	
An	important	use	of	preclinical	models	in	cancer	research	is	for	drug	screening.		
Traditionally,	this	has	been	done	using	established	cell	lines	that,	as	mentioned	above,	
have	 very	 poor	 predictive	 value	 and	 are	 over	 permissive.	Using	 PDX	models	 for	 this	
application	would	be	ideal,	although	at	the	present	time,	cost	and	resources	required	
make	this	approach	unfeasible.	 	As	an	alternative,	some	groups	are	using	short-term	
single	cell	suspensions	and	short-term	culture	in	organoid	bioreactors.		
	
The	process	of	generating	a	PDX	model	clearly	results	in	the	selection	of	tumors	
that	engraft	and	propagate	in	mice.		This	has	been	shown	across	multiple	studies	with	
the	general	 impression	that	more	aggressive	tumors	have	higher	take	rate.	 	 In	breast	
cancer	for	example,	hormone	receptor	negative	tumors	have	a	higher	take	rate	than	
hormone	sensitive	tumors	and	are	overrepresented	in	the	existing	PDX	collections	(16,	
30,	 34).	 	 HBC,	 RCC,	 PDAC	 and	 uveal	 melanoma	 patients	 whose	 tumors	 successfully	
engraft	 show	 the	 worst	 prognosis,	 indicating	 that	 there	 is	 a	 selection	 toward	more	
aggressive	higher	metastatic	tumors	(14,	15,	22,	30,	33,	61).	In	addition,	and	while	this	
is	still	poorly	understood,	it	is	possible	that	tumors	which	engraft	do	so	by	propagation	
of	selected	clones	that	divide	actively	to	form	a	new	tumor	in	the	host	mice	that	is	not	
necessarily	 identical	 to	 the	 parental	 tumor.	 Thus,	 while	 in	 general	 there	 are	 close	
similarities	in	global	genetic	surveys	such	as	unsupervised	clustering	analyses	between	
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a	PDX	model	and	the	original	patient	tumor,	there	are	still	most	probably	changes	 in	
more	 specific	 genes	 and	drug	 targets.	 	 In	 that	 sense,	 some	 studies	have	 shown	 that	
there	are	discrepancies	in	the	expression	of	selected	drug	targets	and	subtle	variations	
in	 the	 expression	 of	 gene	 signatures	 reflecting	 stromal,	 immune	 infiltrate	 or	
angiogenesis	 components.	 	 Indeed,	 several	 studies	 have	 reported	 that	 the	 gene	
expression	 profile	 and	 genetic	 characteristics	 of	 PDX	models	 are	 reminiscent	 of	 the	
cancer	metastasis	and	relapse	environment	(15,	24,	33).	
	
FUTURE	DIRECTIONS	
	
Over	the	last	few	years	there	has	been	a	growing	interest	in	developing	PDX	collections	
and	 using	 them	 for	 different	 cancer	 research	 applications	 (11,	 12).	While	 there	 has	
been	 important	progress	 in	 the	 field,	 there	are	several	 crucial	areas	 that	will	benefit	
from	 additional	 research.	 These	 include	 such	 diverse	 issues	 as:	 implantation	
procedures,	 consideration	 of	 mouse	 host	 strain,	 post	 engraftment	 manipulations,	
robust	application	of	translational	imaging	modalities	in	the	assessment	of	PDX	models	
towards	 the	 elucidation	 of	 imaging	 response	 biomarkers,	 and	 nomenclature	 and	
harmonization	 in	 study	 design	 and	 reporting.	 Furthermore,	 because	 of	 significant	
expansion	 in	 the	 field,	 organized	 and	 collaborative	 efforts	 will	 also	 be	 needed	 to	
optimize	the	use	of	existing	collections	and	the	generation	of	new	ones.		
	
As	mentioned	above,	the	process	of	generating	PDX	models	is,	in	general,	well	
established	and	implemented	in	a	consistent	fashion	by	most	research	groups	(10,	13).		
However,	each	research	group	has	developed	its	own	approach	and	few	comparative	
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methodological	studies	are	available.		Issues	such	as	the	minimum	sample	size	needed,	
best	 preservation	 media,	 the	 need	 to	 add	 other	 components	 such	 as	 matrigel	 or	
mesenchymal	 cells,	 site	 of	 implantation	 (subcutaneous,	 orthotopic	 or	 renal	 cell	
capsula),	 and	 time	spent	on	processing	 the	 specimen	 for	better	 results	are	currently	
unknown.		Of	major	importance,	particularly	for	personalized	medicine	applications,	is	
the	development	of	methods	 to	 increase	engraftment	 rates	and	 to	generate	models	
from	difficult-to-engraft	cancer	types	such	as	prostate	or	hormone	dependent	HBC.		Of	
great	interest	in	this	sense	are	newer	three-dimensional	models	of	glioblastoma,	CRC	
and	 HBC	 for	 example.	 These	 tissue-originated	 spheroids	 are	 generated	 by	 digesting	
and	growing	primary	tumor	cells	under	controlled	culture	conditions	(62).	 	Spheroids	
can	 survive	 for	 several	 days	 under	 in	 vitro	 conditions,	 can	 be	 subjected	 to	 ex	 vivo	
manipulation	and	can	generate	full	tumors,	of	even	well	differentiated	histology,	when	
implanted	in	mice	(63).	 	Likewise,	flow	cytometry	strategies	to	purify	tumor-initiating	
cells	prior	to	implantation	in	mice	can	improve	engraftment	rates	(64).			
	
Once	a	PDX	model	has	been	developed,	there	is	also	interest	in	generating	cell	
lines	 to	 facilitate	 high-throughput	 drug	 screening	 and	 functional	 studies	 (65).		
However,	 as	 discussed	 above,	 any	 ex-vivo	 manipulation	 may	 pre-empt	 significant	
modifications	 in	 fundamental	 biological	 properties	 of	 the	 tumor,	 thus	 compromising	
the	translational	value	of	the	models	(27).	
	
It	 is	now	well	established	that	cancer	is	genetically	heterogeneous	in	an	inter-	
and	 intra-individual	 manner	 and	 that	 there	 is	 a	 genetic	 evolution	 in	 cancer	 as	 the	
tumor	progresses	(66-68).	Thus,	a	PDX	model	generated	from	one	individual	lesion	at	a	
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single	 time	point	 is	 indeed	a	 snapshot	 view	of	 a	 tremendously	dynamic	process	 and	
may	not	be	representative	of	the	full	diversity	of	the	disease.	Furthermore,	the	process	
of	 PDX	 generation,	 as	 discussed	 in	 detail	 above,	 selects	 for	more	 aggressive	 tumors	
and	likely	for	more	aggressive	clones,	with	metastatic	features,	within	the	tumor.	 	At	
present,	 there	are	no	solutions	 to	 this	 issue.	 	However,	 recent	studies	attempting	 to	
generate	PDX	models	from	circulating	tumor	cells	have	shown	promising	early	results	
(69).	 	One	approach	 to	at	 least	partially	overcome	 this	problem	 is	 the	generation	of	
models	from	rapid	autopsy	programs	that	permit	sampling	of	multiple	lesions	from	the	
same	cancer	(70).	In	addition	to	their	role	in	studies	of	cancer	evolution,	these	models	
also	are	a	better	 representation	of	end-stage	disease,	which	 is	where	new	drugs	are	
ultimately	tested.	Furthermore	it	is	to	be	expected	that	the	more	rigorous	grafting	of	
tumors	before,	 during	 and	after	 treatments,	 as	 it	 is	 being	performed	nowadays,	will	
also	 result	 in	 novel	 PDX	 models	 from	 paired	 clinically	 drug-sensitive	 and	 -resistant	
tumors.		
	
One	 key	 aspect	 in	 PDX	 research	 is	 the	 host	 mouse	 model	 used.	 	 With	 the	
premise	that	 immunodeficient	hosts	are	required	to	allow	engraftment,	 investigators	
have	 used	 different	mouse	 strains	 to	 generate	 PDX	 collections.	 	 These	 strains	 differ	
with	 regards	 to	 their	 immune	 system	 deficiencies	 and	 provide	 different	 permissive	
environments	 (Supplementary	 Table	 1).	 The	 prevailing	 notion	 that	 a	more	 severely	
immunodeficient	mouse	 is	a	better	host	has	not	been	properly	assessed.	 	While	 this	
question	 may	 not	 be	 relevant	 for	 small-scale	 experiments,	 large	 preclinical	 studies,	
which	use	hundreds	of	mice,	would	benefit	from	the	use	of	cheaper	and	less	delicate	
strains.	 Of	 major	 interest,	 however,	 is	 the	 development	 of	 mouse	 models	 with	
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reconstituted	immune	systems	from	the	donor	individual,	or	models	able	to	replicate	
human,	 rather	 than	 murine	 stroma	 (71).	 A	 “personalized	 immune”	 mouse,	 with	 a	
robust	 immune	 reconstitution	 with	 hematopoietic	 stem	 cells	 (HSCs)	 aspirated	 from	
bone	marrow	of	an	individual	cancer	patient,	may	provide	a	new	model	to	observe	the	
role	of	the	autologous	immune	response	in	the	PDX	setting	of	the	same	cancer	patient.	
These	models	would	permit	the	testing	of	agents	directed	against	the	immune	system	
or	the	stromal	component.	
	 	
Another	 critical	 requirement	 is	 the	ability	 to	non-invasively	 and	 longitudinally	
monitor	PDX	tumor	growth	kinetics	and	response	to	therapies.		Small	animal	imaging	
techniques	such	as	computed	tomography,	magnetic	resonance	imaging	and	positron-
emission	 tomography	 allow	 for	 detailed	 appraisal	 of	 tumor	 anatomy,	 vascularization	
and	metabolic	activity	(72).	Nevertheless	these	approaches	are	limited	with	respect	to	
high-throughput	 implementation,	 require	 costly	equipment	and	 infrastructure,	and	a	
high	 level	 of	 technical	 expertise.	 Conversely,	 bioluminescence	 imaging	 (BLI)	 requires	
ectopic	transduction	of	a	light-emitting	enzyme	(usually	luciferase)	in	tumor	cells,	but	
represents	a	cost-effective	and	relatively	high	throughput	and	facile	preclinical	imaging	
modality	 (73).	 Recent	 studies	 have	 reported	 efficient	 expression	 of	 exogenous	
proteins,	 including	luciferase,	by	infecting	patient	derived	tumor	cell	suspensions	and	
spheroid	 cultures	 with	 lentiviral	 particles	 (74).	 While	 these	 advances	 attest	 to	 the	
feasibility	 of	 genetic	 modification	 of	 PDX	 tumor	 preparations	 for	 imaging	 purposes,	
their	utility	in	the	routine	implementation	of	BLI	to	follow	PDX	tumors	in	vivo	remains	
to	be	seen.	
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Efforts	 to	 harmonize	 and	 standardize	 study	 design	 and	 data	 analysis	 are	 also	
needed.	 	 For	 PDX	 preclinical	 studies	 to	 be	 fully	 integrated	 in	 clinical	 development	
pipelines,	there	first	needs	to	be	a	consensus	in	the	design	of	preclinical	studies.		This	
includes	areas	such	as	the	number	of	models	representing	the	tumor	heterogeneity	of	
the	majority	of	 tumor	 types,	and	 the	number	of	mice	per	model	 required	 for	 robust	
statistical	 interrogation,	 as	 per	 a	 clinical	 trial.	 Another	 important	 question	 is	 the	
homogeneity	of	the	batch	of	mice	in	which	a	drug	will	be	assayed,	important	when	a	
large	number	of	mice	are	needed.		A	key	question	is	the	efficacy	endpoint	selected	and	
the	 degree	 of	 efficacy	 required	 for	 a	 positive	 result.	 For	 example,	 when	 testing	
conventional	cytotoxic	agents,	tumor	regression	may	be	the	preferred	endpoint,	while	
if	testing	agents	against	the	cancer	stem	cell	compartment	endpoints	such	as	growth	
delay	and	latency	to	growth	after	retransplantation	may	be	favored.		Regardless	of	the	
selected	 endpoint,	 a	 consensus	 is	 needed	 in	 reference	 to	 the	 level	 of	 activity	
considered	sufficient	to	advance	an	agent	to	clinical	development.			
	
		 As	 the	 number	 of	 groups,	 both	 in	 industry	 and	 in	 academia,	 working	 on	
developing	 PDX	 collections	 increases,	 efforts	 to	 develop	 collaborative	 networks	 are	
ongoing.	 These	 networks	will	 likely	 house	 thousands	 of	models	with	well-annotated	
biological,	 clinical	 and	 drug	 response	 data.	 With	 proper	 confidentiality	 and	 data	
protection	 systems,	 this	 information	 can	 be	 shared	 to	 permit	 rapid	 assessment	 of	
model	 availability,	 which	 will	 be	 particularly	 important	 for	 rare	 molecularly-defined	
tumor	 types.	 Furthermore,	 these	 networks	 will	 allow	 the	 conduction	 of	multicenter	
preclinical	 trials	 as	 done	 for	 patients	 under	 a	 single	 protocol	with	 rapid	 accrual	 and	
data	generation.			
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In	 that	 sense,	 within	 Europe	 a	 consortium	 of	 centers	 having	 interest	 and	
significant	 expertise	 in	 PDX	 models,	 has	 now	 emerged:	 EurOPDX	 is	 an	 initiative	 of	
translational	and	clinical	researchers	across	Europe	having	the	common	goal	to	create	
a	 network	 of	 clinically	 relevant	 and	 annotated	 models	 of	 human	 cancer,	 and	 in	
particular	 PDX	models.	 The	 primary	 goal	 of	 our	 initiative	 is	 to	 share	 PDX	models	 in	
diverse	cancer	pathologies,	in	order	to	constitute	a	unique	collection	reproducing	the	
heterogeneity	 of	 human	 cancer.	Supplementary	 Table	 2	 provides	 a	 summary	 of	 the	
models	and	the	level	of	characterization	of	those	models	currently	available	across	the	
EurOPDX	Consortium.		
	
A	 shared	database	with	harmonized	annotation	of	models	will	be	established	
and	 integrative	 systems-based	 analyses	 developed	 to	 elucidate	 novel	 therapeutic	
strategies	 and	 uncover	 predictive	 biomarkers	 for	 personalized	 cancer	 treatment.	
Annotation	of	the	models	will	 include	anatomo-pathological	data,	clinico-pathological	
data	 from	 the	 patients	 the	 PDX	 were	 derived	 from,	 deep	 molecular	 profiling	 in	
particular	with	gene	expression,	copy	number	alterations	and	proteomics	platforms,	as	
well	 as	 pharmacogenomic	 data	 corresponding	 to	 current	 anticancer	 therapies.	
Additional	 technologies	 such	 as	 imaging	 are	 increasingly	 being	 used	 and	 the	 ideal	
database	will	also	include	such	data	as	well	as	scanned	images	of	pathology	slides	(75).		
In	 this	 way	 the	 Consortium	 will	 be	 able	 to	 quickly	 include	 any	 newly	 developed	
multimodal	 prognostic	 and	 predictive	 tool	 in	 the	 analysis	 pipeline.	Making	 the	 data	
available	for	the	analysis	is	not	a	trivial	task	as	it	 implies	standardization	of	platforms	
used	for	molecular	characterization,	data	acquisition,	data	curation,	normalization	and	
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quality	control.	Moreover,	and	as	discussed	above,	harmonization	and	standardization	
of	working	practices	for	the	implementation	and	use	of	PDX	models,	and	in	particular	
for	the	performance	of	more	reproducible	and	predictive	multicenter	preclinical	trials,	
will	be	a	key	objective	of	the	network.		
	
Hypotheses	will	then	be	validated	in	proof-of-concept	collaborative	multicenter	
xenopatient	trials	within	molecularly	defined	tumor	subsets	and	on	a	population	scale,	
as	 a	 prelude	 for	 prospective	 clinical	 trials	 in	 humans.	 The	 consortium	 will	 be	 in	
absolute	 compliance	 with	 European	 rules	 for	 the	 use	 of	 experimental	 animals.	 A	
coordinated	 and	 rational	 design	 of	 the	 experiments,	 troubleshooting	 and	 sharing	 of	
positive	and	negative	results	across	the	various	centers	will	enable	a	reduction	in	the	
overall	number	of	experimental	animals	utilized	and	optimize	the	use	of	each	precious	
patient	 sample,	 avoiding	 unnecessary	 replicas	 of	 experiments,	 while	maximizing	 the	
statistical	significance	and	robustness	of	the	data.	
	
Finally,	 the	 performance	 of	 research	 programs	 among	 this	 academic	
consortium	will	allow	to	address	the	current	 limitations	of	the	PDX	models	described	
above	and	advance	their	use	as	clinically	relevant	cancer	models.	
		
Through	the	building	of	this	network	and	its	collaboration	with	pharmaceutical	
companies	 and	 SMEs,	 the	 EurOPDX	 initiative	will	 accelerate	 the	emergence	of	 novel	
therapeutic	strategies	with	a	real	impact	on	quality	of	life	and	overall	survival	of	cancer	
patients	 through	more	predictive	preclinical	or	 "co-clinical"	data,	ultimately	 reducing	
attrition	rate	in	oncology	clinical	trials	in	Europe.	
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CONCLUSIONS	
	
Over	 the	 last	 decade	 there	 has	 been	 an	 interest	 in	 developing	 and	 characterizing	
collections	 of	 PDX	 models	 from	 different	 cancer	 types,	 which	 are	 now	 available	 at	
academic	and	non-profit	organizations.		These	models	are	becoming	an	integral	part	of	
the	drug	development	arena,	including	drug	screening	and	biomarker	development.		In	
addition,	PDX	models	bear	the	promise	of	assisting	clinical	trial	designs	as	well	as	being	
integrated	 in	personalized	medicine	strategies.	 	 It	 is	envisioned	 that	PDX	models	will	
eventually	play	a	broader	role	 in	the	drug	development	process	and	become	a	must-
have	element	in	that	process.	At	present,	however,	there	are	still	some	critical	issues	
that	 must	 be	 addressed	 to	 make	 this	 platform	 more	 useful	 and	 informative.	 	 This	
includes	 increasing	the	take	rate	and	time	to	model	generation,	recapitulation	of	the	
human	stroma	and	immune-related	elements,	as	well	as	strategies	to	develop	models	
more	 representative	 of	 different	 cancer	 entities,	 tumor	 heterogeneity	 and	
chemorefractory	 patients.	 Finally,	 initiatives	 to	 harmonize	 nomenclature,	 study	
designs	 and	 procedures	 are	 needed.	 We	 propose	 that	 the	 new	 European	 EurOPDX	
initiative,	 which	 represents	 a	 PDX	 collaborative	 consortium,	 will	 offer	 a	 unique	
opportunity	to	address	translational	challenges	in	oncology	research.	
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LEGEND	TO	FIGURES	
	
Figure	1.		Proposed	Preclinical	Screening	and	Biomarker	Study	in	PDX	models.	
This	figure	graphically	illustrates	some	of	the	key	elements	of	a	preclinical	study	in	PDX	
models.	These	studies	are	likely	to	be	more	informative	late	in	preclinical	development	
or	 in	 parallel	 to	 phase	 I	 safety	 and	 pharmacology	 testing.	 Models	 can	 be	 selected	
based	 on	 tumor	 types	 or	 on	 predefined	 molecular	 subtypes	 if	 that	 information	 is	
known	and	of	interest,	or	both.		We	propose	a	two-step	approach.	In	Step	1,	a	limited	
number	of	models	can	be	tested	with	the	agent	at	doses	and	schedules	known	to	be	
effective	 and	 pharmacologically	 active	 in	 earlier	 preclinical	 studies.	 Study	 endpoints	
need	 to	 be	 carefully	 selected	 based	 on	 the	 agent's	mechanism	of	 action.	Data	 from	
Step	 1	 can	 be	 used	 to	 proceed	 to	 Step	 2	 and	 to	 redefine	model	 selection	 based	 on	
molecular	understanding	of	responsive	models.	In	Step	2,	a	larger	repertoire	of	models	
can	be	treated.		At	the	conclusion	of	the	study	a	decision	needs	to	be	made	to	proceed	
to	clinical	development	and	prioritize	biomarkers	to	be	explored	in	the	clinical	phase.	
	
Figure	2.		Co-clinical	trial	approach	with	PDX	models	
A	 new	 version	 of	 the	 co-clinical	 trial	 concept	 is	 presented	 in	 which	 a	 PDX	model	 is	
developed	 from	 a	 patient	 enrolled	 and	 treated	 in	 a	 clinical	 trial	with	 a	 novel	 agent.		
This	approach	permits	to	have	models	with	validated	clinical	outcome	data	that	can	be	
used	 to	 interrogate	mechanisms	 of	 response	 and	 resistance	 as	well	 as	 strategies	 to	
increase	response	and	overcome	resistance,	for	example,	combination	strategies.	
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Figure	3.		Personalized	medicine	strategy	
Depicted	in	this	figure	is	a	strategy	for	individualizing	medicine	that	integrates	genomic	
analysis	of	a	patient	tumor	with	testing	in	Avatar	mouse	models.		The	genomic	analysis	
of	 a	 patient	 tumor	 is	 likely	 to	 show	 tens	 of	 potential	 therapeutically	 targetable	
mutations.		Mining	of	genomic-drug	response	databases	such	as	the	CCLE	or	the	NCI60	
as	 well	 as	 knowledge	 of	 these	 mutations	 is	 likely	 to	 result	 in	 several	 potential	
therapeutic	 regimens	 for	a	 given	patient.	 The	Avatar	model	 can	be	used	 to	 test	 and	
rank	these	potential	treatments	to	be	administered	to	the	patient.		A	post	hoc	analysis	
of	 this	 information	 can	 be	 added	 to	 existing	 data	 to	 further	 feed	 into	 the	 existing	
databases.	
	
SUPPLEMENTARY	TABLES	AND	FIGURES	
	
Supplementary	Table	1.	Most	commonly	used	immunodeficient	mouse	strains	
This	 Table	 summarizes	 the	 principal	 features	 of	 the	most	 common	 immunodeficient	
mouse	strains	used	to	generate	PDX	models.	
	
Supplementary	Table	2.	Available	PDX	Models	at	the	EurOPDX	Consortium	
This	 Table	 provides	 a	 summary	 of	 validated	 models	 currently	 available	 across	 the	
EurOPDX	Consortium,	with	their	current	level	of	genetic	and	genomic	characterization.	
	
Supplementary	Figure	1.		Genomics	Mimicry	for	Personalized	Cancer	Treatment	
A	model	 for	 personalized	 cancer	 treatment,	 using	 HBC	 as	 an	 example,	 is	 proposed.		
Knowing	the	response	to	treatment	agents	of	genetically	defined	PDX	models	can	be	
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used	 to	match	 patients	with	 similar	 genetic	 profile,	with	 the	 expectations	 that	 drug	
response	will	be	similar.	
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Table	1.		Key	Methodological	Aspects	of	Selected	PDX	Collections	
This	Table	provides	a	summary	of	the	methodological	approaches	used	to	generate	the	most	comprehensive	PDX	collections	currently	
available.	Abbreviations	are:		CRC:	colorectal	cancer;	s.c.:	subcutaneous	implantation;	HBC:	human	breast	cancer;	NSCLC:	non-small	cell	lung	
cancer;	PDAC:	pancreatic	ductal	adenocarcinoma;	NR:	not	reported;	RCC:	renal	cell	cancer;	SCCHN:	squamous	cell	carcinoma	of	the	head	and	
neck;		SCC:	squamous	cell	carcinoma;	FOM:		floor	of	the	mouth;	FOT:	floor	of	the	tongue;	NOD/SCID:	Non-obese	diabetic/severe	combined	
immunodeficiency	disorder;	NSG:	NOD/SCID/IL2λ-receptor	null.	
Reference	 Tumor	
	Type	
Available		
Models	
Origin	 Procurement	 Processing	 Mice	
Strain	
Implantation	
Site	
Engraftment	
Rate	
(28)	 CRC	 130	 Metastasis	 Surgery	 Fresh	tumor	pieces		
in	matrigel	
NOD/SCID	 s.c.	 87	%	
(29)	 CRC	 54	 Primary	(35)	
Metastasis	
(19)	
Surgery	 Fresh	tumor	pieces	 Nude	 s.c.	 64	%	
(76)	 CRC	 41	 Primary		 Surgery	 Fresh	tumor	pieces	 Nude	 Orthotopic	 89.1%	
(34)	 HBC	 25	 Primary	 Surgery	 Fresh	tumor	pieces	 Nude	 s.c.	 13	%	
(30)	 HBC	 12	 Primary	(4)	
Metastasis	
(8)	
Surgery/	
Fluid	drainage	
	Fresh	tumor	pieces	
in	matrigel	
NOD/SCID	with	estrogen	
supplementation	for		
ER+	tumors	
Mammary	fat	
pad	
27	%	
(16)	 HBC	 24	 Primary	 Biopsies/	
Surgery/	
Fluid	drainage		
Fresh	tumor	pieces	
	
SCID/Beige	and	NSG	w/wo	
estrogen	and	immortalized	
human	fibroblasts	
Mammary	fat	
pad	
3-21	%	
(21)	 NSCLC	 25	 Primary	 Surgery	 Fresh	tumor	pieces	
	
NOD/SCID	 s.c.	 25	%	
(20)	
(20)(22)	
NSCLC	 32	 Primary	 Surgery	 Fresh	tumor	pieces	
	
NOD/SCID	 Renal	capsule	 90	%	
(33)	 PDAC	 42	 Primary		 Surgery	 Fresh	tumor	pieces			
in	matrigel	
Nude	 s.c.	 61	%	
(26)	 PDAC	 14	 Primary	 Surgery	 Fresh	tumor	pieces		 Nude	 s.c.	 NR	
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in	matrigel	
(77)	 PDAC	 16	 Primary	(11)	
Metastasis	
(5)	
Surgery	 Fresh	tumor	pieces	 Nude	 Orthotopic	 62%	
(78)	 SCCHN	 22	 Primary	 Biopsy/	
Surgery	
Fresh	tumor	pieces	
in	matrigel	
NSG	 s.c.	 85	%	
(25)	 SCCHN/SCC	 21	 Primary	 Surgery	 Fresh	tumor	pieces	
in	matrigel	
Nude	 s.c.	
FOM/FOT	
54	%	
(14)	 Uveal	
Melanoma	
25	 Primary	(73)	
Metastasis	
(17)	
Surgery	 Fresh	tumor	pieces	 NOD/SCID	 s.c.	 28	%	
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Table	2.		Fidelity	and	Stability	of	PDX	Models	
This	Table	summarizes	the	data	from	different	studies	in	which	PDX	models	have	been	compared	to	donor	tumors	using	a	variety	of	methods.	
Abbreviations	are:		PDX:	patient	derived	xenograft;	CRC:		colorectal	cancer;	CNA:		copy	number	alteration;	aCGH:		comparative	genomic	
hybridization	array;	GE:		gene	expression;	HBC:	human	breast	cancer;	IHC:		immunohistochemistry;	RPPA:	reverse	phase	protein	array;	SNP:		
single	nucleotide	polymorphism;	NSCLC:		non-small	cell	lung	cancer;	PDAC:	pancreatic	ductal	adenocarcinoma;	RCC:		renal	cell	cancer;	SCCHN:		
squamous	cell	carcinoma	of	the	head	and	neck;	SCC:		squamous	cell	carcinoma;	NGS:		next	generation	sequencing.		
	
Reference	 Tumor	
	Type	
Original	Tumor-First	Passage	 Subsequent	Passages	
(28)	 CRC	 Conserved	histopathology	characteristics	between	donor	and	PDX	model.	
Similarities	in	CNA	between	donor	and	PDX	models.	
Consistent	KRAS,	NRAS,	BRAF	and	PI3K	mutation	status.	
Stable	CNA	across	passages.	
	
(29)	 CRC	 Unsupervised	clustering	analysis	using	aCGH	and	GE	shows	donor	tumors	and	PDX	
clustered	together.	
203	differentially	expressed	annotated	genes	correspond	to	stroma-related	genes	and	
pathways.	
Stable	aCGH	and	GE	profile	across	
passages.	
(31,	34)	 HBC	 Conserved	IHC	expression	of	ER,	PR	and	HER2.	
Analysis	of	CNA	showed	14/18	paired	tumors-PDX	shared	more	than	56	%	CNV.	
16/18	paired	tumors-PDX	clustered	together	in	unsupervised	hierarchical	analysis.	
PDX	showed	losses	in	176	and	gains	in	202	chromosome	regions	compared	to	primary	
tumors.	
Stable	GE	profile	with	less	than	5	%	variations.	
Stable	CNA	and	GE	profile	across	
passages.		
Variations	in	stromal	related	genes.	
(30)	 HBC	 Conserved	histopathology	characteristics	between	donor	and	PDX	model.	
Conserved	IHC	expression	for	CK,	E-cadherin,	B-catenin,	vimentin,	ER,	PR	and	HER2.	
Unsupervised	clustering	analysis	using	GE	shows	donor	tumors	and	PDX	clustered	
together.	
Maintenance	in	the	pattern	of	CNA.	
Intrinsic	breast	cancer	subtypes	concordance	between	donor	tumors	and	PDX.	
Stable	IHC	profile	over	time.	
(16)	 HBC	 Conserved	histopathology	characteristics	between	donor	and	PDX	model.	
Conserved	IHC	expression	for	CK,	p53,	Ki67,	ER,	PR,	HER2	and	EGFR.	
Stable	histopathological	and	IHC	
expression.	
	 51	
Intrinsic	breast	cancer	subtypes	represented	in	PDX	models.	 Stable	GE,	RPPA	and	SNP	across	
passages.	
	
(21)	 NSCLC	 Conserved	histopathological	characteristics	between	donor	and	PDX	model.	
Conserved	IHC	expression	of	Ki-67	and	EpCAM.	
Unsupervised	clustering	analysis	using	GE	shows	donor	tumors	and	PDX	clustered	
together	with	correlation	coefficient	ranging	from	0.78-0.94.	
134	differentially	expressed	genes	correspond	to	cell	adhesion	and	immune	response	
genes	and	pathways.	
	
(26,	33)	 PDAC	 Concordance	in	mutations	in	KRAS	and	DPC4.	
Conserved	GE	profile	(R2	=	0.69).	
Concordance	in	gemcitabine	
response	between	F3	and	F6.	
Enrichment	in	angiogenesis	gene	
signature	in	F5.	
(25)	 SCC/SCC
HN	
Conserved	histopathological	characteristics	between	donor	and	PDX	model.	
High	correlation	(R2	=	0.91)	in	EGFR	expression.	
High	correlation	(R2	∼	0.8)	in	GE.	
Variation	in	immune-related	pathways.	
High	correlation	(R2	∼	0.94)	in	GE	
from	F2-F4	
Concordance	in	cetuximab	
response	between	F2	and	F4.	
(15)	 RCC	 Conserved	histopathological	characteristics.	
Donor	and	PDX	model	cluster	together	in	unsupervised	hierarchical	clustering	analysis	
using	GE.	
PDX	retained	CNA	from	the	donor	tumor.	
Similar	mutation	landscape	in	NGS	studies.	
Conserved	histopathological	
characteristics.	
Serial	passages	clustered	together	
in	unsupervised	hierarchical	
clustering	analysis.	
Maintains	CNV	of	the	donor	tumor.	
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Table	3:		Studies	Correlating	PDX	Treatment	Results	with	Clinical	Data	
This	Table	provides	a	summary	of	studies	in	which	PDX	models	from	different	cancer	types	have	been	treated	with	agents	used	in	the	clinical	
care	of	these	patients.	Abbreviations	are:		PDX:	patient	derived	xenograft;	RR;	response	rate;	CRC:	colorectal	cancer;	WT:	wild	type;	TR:	tumor	
regression;	N/A:	not	available;	T/C:		treated	divided	by	control;	BC:	human	breast	cancer;	TGI:		tumor	growth	inhibition;	GD:		growth	delay;	AC:		
adriamycin-cyclophosphamide;	GnRH:	gonadotrophin	releasing	hormone;	NSCLC:	non-small	cell	lung	cancer;	SCCHN:	squamous	cell	carcinoma	
of	the	head	and	neck;	RCC:	renal	cell	cancer;	PDAC:	pancreatic	ductal	adenocarcinoma.		
	
Tumor	Type	
(Reference)	
Definition	Activity	 Standard	Agent	 n	 RR	(%)	 Clinical	Correlates	
CRC		
CRC	KRAS	WT	
(28)	
TR	>	50	%	 Cetuximab	
Cetuximab	
47	
38	
10	
17		
N/A	
CRC	(29)	 T/C	<	10	%	 5-Fluorouracil	
Oxaliplatin	
Irinotecan	
Cetuximab	
52	
52	
49	
52	
13	
0	
38	
26	
N/A	
HBC	(34)	 Complete	response	
TGI	>	50	%	or	T/C	GD	>	2	
fold	
AC	
Docetaxel	
Trastuzumab	
GnRH	antagonist	
17	
17	
2	
1	
76		
47	
50	
100	
Response	to	treatment	in	PDX	model	
was	concordant	with	clinical	data	in	
5/7	patients.	
HBC	(16)	 RR	>	30	%	 Docetaxel	
Doxorubicin	
Trastuzumab-Lapatinib	
7	
4	
1	
14	
0	
100	
92	%	correlation	between	clinical	
responses	and	responses	in	PDX	
NSCLC	(20)	 Statistically	significant	
decrement	in	tumor	area	in	
treated	vs	control	tumors	
Cisplatin-Vinorelbine	
Cisplatin-Docetaxel	
Cisplatin-Gemcitabine	
32	
19	
16	
28	
42	
44	
PDX	models	from	6/7	patients	with	
early	recurrent	disease	were	resistant	
to	the	clinically	used	regimen.	
NSCLC	(21)	 T/C	<	5	%	 Etoposide	
Carboplatin	
Gemcitabine	
Paclitaxel	
25	
25	
25	
25	
4	
12	
12	
16	
NA	
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Vinorelbine	
Cetuximab	
Erlotinib	
11	
25	
25	
0	
12	
1	
SCCHN	(25)	 T/C	<	20	%	 Cetuximab	 11	 9	%	 N/A	
RCC	(15)	 Statistically	significant	
differences	in	TGI	
Sunitinib	
Sirolimus	
Erlotinib	
8	 Active	
Active	
In	active	
NA	
PDAC	(26)	 T/C	<	20	%	 Gemcitabine	
Erlotinib	
Temsirolimus	
14	 36	
0	
0	
NA	
PDAC	(33)	 TGI	>	85	%	 Gemcitabine	 23	 17	%	 Response	to	Gemcitabine	in	the	PDX	
model	predicted	longer	time	to	
progression	in	patients.		
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Supplementary	Table	1.		Most	commonly	used	immunodeficient	mouse	strains*	
This	Table	summarizes	the	principal	features	of	the	most	common	immunodeficient	mouse	strains	used	to	generate	PDX	models.	Modified	
from	“The	Jackson	Laboratory”	(www.jax.org).		Abbreviations	are:	NK:	Natural	killer;	SCID:	severe	combined	immunodeficiency	disorder;	
NOD/SCID:	Non-obese	diabetic;	NSG:	NOD/SCID/IL2λ-receptor	null.	
	
Mouse	Strain	 Deficiency	 Advantages	 Disadvantages	 Applications	
Nude	(nu)	 No	functional	T	cells	
Well	characterized.	
High	take-rate	of	human	
tumors.	
Hairless:	improved	surgery	
and	tumor	monitoring.	
Functional	B	and	NK	cells.	
T-cell	functionality	
increases	with	age.	
Transplantation	of	murine	and	human	
(xenogeneic)	tumors	for	imaging,	
metastasis	and	new	therapies	studies.	
SCID	(scid)	 No	functional	T	and	B	cells	
Better	engraftment	of	
allogeneic	and	xenogeneic	
tumor	cells	and	tissues	than	
in	Nude	strain.	
Functional	NK	cells.	
Spontaneous	lymphomas.	
Transplantation	of	murine	and	human	
(xenogeneic)	tumors	for	imaging,	
metastasis	and	new	therapies	studies.	Low	
levels	of	engraftment	of	human	PBMC	and	
fetal	hematopoietic	tissues.	
NOD-SCID	 No	functional	T	and	B	cells,	NK	cells	impaired	
Well	characterized.	
Low	NK	cell	activity.	
Very	low	leakiness	with	age.	
High	incidence	of	
lymphomas.	
Radiosensitive.	
Higher	levels	of	engraftment	of	PBMC	and	
hematopoietic	stem	cells	compared	with	
the	SCID	strain.	
NOD-SCID	
IL2rgnull	
(NSG)	
No	functional	T,	B	and	
NK	cells	
Lymphoma-resistant.	
Excellent	engraftment	of	
allogeneic	and	xenogeneic	
tumor	cells	and	tissues.	
Suitable	for	analysis	of	
human	cancer	stem	cells	
and	metastasis.	
Not	well	characterized.	
Increased	levels	of	growth,	development	
and	differentiation	of	human	pluripotent	
stem	cells	and	human	tissue	engrafted	by	
intravenous,	intrahepatic,	intraperitoneal	
and	intra-bone	marrow	injection.	
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Supplementary	Table	2.		Available	PDX	Models	at	the	EurOPDX	Consortium	
	
This	Table	provides	a	summary	of	validated	models	currently	available	across	the	EurOPDX	Consortium,	with	their	current	level	of	genetic	and	
genomic	characterization	(CNA:	copy	number	alterations,	GEP:	gene	expression	profiling).	
	
Primary	Tumor	Type	 Number	of	
Models	
Pathology	 Origin	 Annotated	
Clinical	Data	
Biological		
Data	
Pancreatic	cancer	 229	 Ductal	adenocarcinoma:	222	
Ampullary	adenocarcinoma:	6	
Neuroendocrine:	1	
Primary	tumor:	206	
Metastasis:	23	
197	 GEP:	125	
CNA:	102	
Exomic	Sequencing:	86	
Colorectal	 618	 Adenocarcinoma:	617	
Neuroendocrine:	1	
Primary	tumor:	245		
Metastasis:	373	
618	 GEP:	344	
CNA:	72	
Exomic	Sequencing:	113	
Breast	 107	 Invasive	ductal	carcinoma:	101	
Lobular:	4	
Mucinous:	2	
Primary	tumor:	88	
Metastasis:	19	
107	 GEP:	74	
CNA:	42	
Exomic	Sequencing:	40	
Ovary	 134	 Adenocarcinoma:	124	
Carcinoma:	2	
Carcinosarcoma:	8	
Primary	tumor:	119	
Metastasis:	15	
120	
	
GEP:	5	
Exomic	sequencing:	27	
Lung	 68	 Adenocarcinoma:	21	
Squamous	cell	carcinoma:	20	
Large	cell	carcinoma:	15	(3	
neuroendocrine)	
Small	cell	carcinoma:	12	
Primary	tumor:	52	
Metastasis:	16	
33	 Exomic	Sequencing:	9	
Mesothelioma	 3	 -	 Primary	tumor:	1	
Metastasis:	2	
1	 Exomic	sequencing:	1	
Melanoma	 117	 Skin	melanoma:	100	
Uveal	melanoma:	17	
Primary:	13	
Metastasis:	104	
52	 GEP:	19	
CNA:	3	
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Exomic	Sequencing:	24	
Brain	 52	 Glioblastoma:	52	 Primary	tumor:	52	 52	 CNA:	1	
Exomic	Sequencing:	51	
Endometrial	 64	 Adenocarcinoma:	56	
Carcinosarcoma:	8	
Primary	tumor:	56	
Metastasis:	8	
64	 -	
Head&Neck	 13	 -	 Primary	tumor:	10	
Metastasis:	3	
3	 -	
Testicular	 16	 Embryonal	carcinoma:	5	
Choriocarcinoma:	4	
Yolk	sac	tumor:	3	
Mixed:	4	
Primary	tumor:	13	
Metastasis:	3	
16	 GEP:	8	
CNA:	8	
Exomic	Sequencing:	10	
Kidney	 26	 Clear	cell	tumor:	24	
Papillary	tumor:	2	
Primary	tumor:	24	
Metastasis:	2	
26	 -	
Sarcoma	 32	 Osteosarcoma:	13	
Soft	tissue	sarcoma:	19	
Primary	tumor:	22	
Metastasis:	10	
32	 GEP:	11	
CNA:	9	
Cholangiocarcinoma	 6	 Adenocarcinoma:	6	 Primary	tumor:	6	 3	 GEP:	2	
CNA:	2	
Exomic	Sequencing:	2	
Gastric	 7	 Adenocarcinoma:	7	 Primary	tumor:	6	
Metastasis:	1	
7	 -	
Esophagus	 2	 Adenocarcinoma:	2	 Primary	tumor:	1	
Metastasis:	1	
2	 -	
Lymphoma	 3	 Large	B	cell:	3	 -	 3	 -	
Pediatrics	 1	 Hepatoblastoma:	1	 Metastasis:	1	 1	 -	
	
